Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vext ScienceFRA:VV5 -36.03%62 PB Ratio is 0.46 as of Jul. 14, 2026, which is 36% below its 10-year median of 0.72. GuruFocus rates FRA:VV5 with a GF Score™ of 62/100 and a GF Value™ of €0.92. The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Vext Science ranks better than 82.41% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-14), Vext Science's share price is €0.087. Vext Science's Book Value per Share for the quarter that ended in Mar. 2026 was €0.19. Hence, Vext Science's PB Ratio of today is 0.46.
The historical rank and industry rank for Vext Science's PB Ratio or its related term are showing as below:
FRA:VV5'
s PB Ratio Range Over the Past 10 Years
Min: 0.26 Med: 0.72 Max: 3.61
Current: 0.76
During the past 9 years, Vext Science's highest PB Ratio was 3.61. The lowest was 0.26. And the median was 0.72.
FRA:VV5's PB Ratio is ranked better than 82.41% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs FRA:VV5: 0.76
During the past 12 months, Vext Science's average Book Value Per Share Growth Rate was -28.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -22.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.40% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Vext Science was 17.80% per year. The lowest was -23.30% per year. And the median was -10.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vext Science PB Ratio Related Terms
Vext Science PB Ratio Historical Data
* Premium members only.
The historical data trend for Vext Science's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vext Science's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vext Science's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vext Science (FRA:VV5) has a PB Ratio of 0.46 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vext Science and its competitors. This is 36% below median its historical median of 0.72. Over the past decade, Vext Science's PB Ratio has ranged from 0.26 to 3.61. According to the industry distribution chart, Vext Science ranks #162 out of 921 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Vext Science's PB Ratio too high?
Vext Science's current PB Ratio of 0.46 is 36% below median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 3.61. The Drug Manufacturers industry median PB Ratio is 1.90. Vext Science's value of 0.46 is 75.8% below this industry median. Based on the distribution chart, Vext Science ranks #162 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vext Science has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #162 out of 921 companies for PB Ratio. This places Vext Science in the top 18% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.90. Vext Science's value of 0.46 is 75.8% below this benchmark. Historically, Vext Science's own PB Ratio has ranged from 0.26 to 3.61 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 1.90, Vext Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vext Science's current PB Ratio of 0.46 is 75.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current PB Ratio is 0.46, which is 36% below median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current PB Ratio of 0.46. The stock's GF Value™ is €0.92, compared to a current price of €0.09 — trading 90.5% below its estimated fair value. The current PB Ratio is 0.46, which is 36% below median its 10-year median of 0.72 and 75.8% below the Drug Manufacturers industry median of 1.90. Vext Science's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current PB Ratio is 0.46 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.09 is trading 90.5% below its estimated GF Value™ of €0.92.
Key valuation signals for FRA:VV5:
PB Ratio: 0.46 (36% below median its 10-year median of 0.72)
GF Value™: €0.92 vs. price of €0.09 (90.5% below fair value)
Industry Position: 75.8% below the Drug Manufacturers median (#162 of 921)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
62GF Score
Get the complete analysis for FRA:VV5
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
